News
RGEN
--
0.00%
--
Repligen (RGEN) Earnings Expected to Grow: Should You Buy?
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3d ago
Repligen to Report Third Quarter 2021 Financial Results
Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT
GlobeNewswire · 10/14 11:49
Exane BNP Paribas Initiates Coverage On Repligen with Outperform Rating, Announces Price Target of $330
Exane BNP Paribas initiates coverage on Repligen (NASDAQ:RGEN) with a Outperform rating and announces Price Target of $330.
Benzinga · 10/14 11:04
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Repligen Corporation ( NASDAQ:RGEN ) saw a significant share price rise of over 20% in the past couple of months on the...
Simply Wall St. · 09/29 15:27
Craig Hallum Adjusts Repligen PT to $368 From $258, Maintains Buy Rating
MT Newswires · 09/27 11:17
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
Zacks.com · 09/24 15:43
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.
Zacks · 09/22 15:40
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
Zacks.com · 09/21 16:07
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
Zacks.com · 09/21 13:34
Brown Capital Management Small Company Fund Buys 10x Genomics Inc, Smartsheet Inc, Alarm. ...
GuruFocus News · 09/18 18:38
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
Zacks.com · 09/17 14:58
Keybanc Maintains Overweight on Repligen, Raises Price Target to $335
Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $255 to $335.
Benzinga · 09/17 08:36
KeyBanc Raises Price Target on Repligen to $335 From $255, Keeps Overweight Rating
MT Newswires · 09/17 07:38
Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal
Benzinga · 09/16 17:08
Repligen To Acquire Avitide For $150M
Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised o...
Benzinga · 09/16 11:43
BRIEF-Repligen Reports Agreement To Acquire Avitide
reuters.com · 09/16 11:43
Repligen to Acquire Chromatography Developer Avitide in $150 Million Cash-And-Stock Deal
MT Newswires · 09/16 08:28
aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923
aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.
Zacks · 09/14 15:27
Chief Executive Officer Of Repligen Trades $8.18 Million In Company Stock
Anthony Hunt, Chief Executive Officer at Repligen (NASDAQ:RGEN), made a large buy and sell of company shares on September 9, according to a new SEC filing.
Benzinga · 09/14 15:15
Insider Sell: Repligen
MT Newswires · 09/14 08:16
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen Corp through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.